Ptc Therapeutics (PTCT) Total Debt (2012 - 2026)

Ptc Therapeutics' Total Debt history runs 15 years deep, the most recent figure standing at $305.0 million for Q1 2026.

• On a quarterly basis, Total Debt fell 42.87% year-over-year to $305.0 million in Q1 2026; TTM through Mar 2026 was $305.0 million, a 42.87% decrease from a year earlier, with the FY2025 full-year figure at $283.0 million, down 47.9% from the prior year.
• Total Debt improved to $305.0 million in Q1 2026 per PTCT's latest filing, from $283.0 million in the prior quarter.
• Across five years, Total Debt topped out at $679.0 million in Q3 2023 and bottomed at $283.0 million in Q4 2025.
• The 5-year median for Total Debt is $534.0 million (2025), against an average of $493.4 million.
• Across the five-year window, Total Debt surged 90.27% in 2023 and slumped 47.9% in 2025, its largest moves.
• Year by year, Total Debt stood at $643.9 million in 2022, then fell by 25.68% to $478.5 million in 2023, then rose by 13.52% to $543.2 million in 2024, then slumped by 47.9% to $283.0 million in 2025, then rose by 7.79% to $305.0 million in 2026.
• Per Business Quant, the three latest PTCT Total Debt figures stand at $305.0 million (Q1 2026), $283.0 million (Q4 2025), and $286.3 million (Q3 2025).